Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial   NEW YORK – September 10, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome…

Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference

Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference   NEW YORK – September 8, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…